Q2: $81.9 million
Full Year: $341.1 million
Earnings per Share
Full Year: $0.75
•Before last quarter, Medidata’s earnings had exceeded
analyst expectations for five straight quarters. Over that
time frame, the stock more than doubled.
•However, when the company failed to meet expectations
in April, the stock slipped as much as 30%.
•Because it currently trades for 54 times trailing earnings,
the stock will continue to move heavily based on how it
performs versus Wall Street expectations.
Investors will be
watching to see if
more and more drug
Medidata to manage
•Medidata has consistently added to its customer base
by roughly 5% on a quarter-by-quarter basis.
•If the company can reach 440 total customers,
investors will know that the company is still gaining
traction with drug and life sciences companies.
The life sciences
industry is only so
big. Investors believe
revenues by offering
•For most of the history of the company, Medidata’s
“Rave” cloud system has accounted for most of the
•However, recently Medidata has started adding more
add-on products that not only add value, but make
switching costs very high for customers.
•If Medidata can grow its percentage of customers using
more than one product to 54%, that would be a great
sign for investors.